The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

Per CNBC, Eli Lilly is widening its lead in the weight-loss drug market while Novo Nordisk scrambles to win back ground and rebuild investor confidence in its pipeline.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton